Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Safety and efficacy of glasdegib for R/R AML

Andrius Žučenka • 10 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Cytarabine Glasdegib

Andrius Žučenka, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the safety and efficacy of glasdegib for relapsed/refractory (R/R) acute myeloid leukemia (AML). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Andrius Žučenka

The effectiveness of sequential alloSCT in patients with venetoclax-exposed R/R AML or MDS-IB2 3:29
The effectiveness of sequential alloSCT in patients with venetoclax-exposed R/R AML or MDS-IB2
Andrius Žučenka • 15 Jun 2025
ADVANCED: a novel conditioning regimen for alloSCT in patients with adverse-risk AML 3:21
ADVANCED: a novel conditioning regimen for alloSCT in patients with adverse-risk AML
Andrius Žučenka • 15 Jun 2025
Efficacy and safety of combining venetoclax with cytarabine and actinomycin D in R/R AML 3:13
Efficacy and safety of combining venetoclax with cytarabine and actinomycin D in R/R AML
Andrius Žučenka • 15 Jun 2025
The evolving treatment paradigm for unfit patients with AML 4:50
The evolving treatment paradigm for unfit patients with AML
Andrius Žučenka • 7 Dec 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals